US Stock MarketDetailed Quotes
BNR Burning Rock Biotech
- 5.305
- +1.065+25.12%
Close Nov 27 16:00 ET
- 5.305
- 0.0000.00%
Post 20:01 ET
54.42MMarket Cap-695P/E (TTM)
5.450High4.080Low22.82KVolume4.080Open4.240Pre Close113.79KTurnover0.50%Turnover RatioLossP/E (Static)10.26MShares9.98752wk High0.58P/B24.34MFloat Cap2.62052wk Low--Dividend TTM4.59MShs Float397.500Historical High--Div YieldTTM32.31%Amplitude2.620Historical Low4.987Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Burning Rock Biotech Stock Forum
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
Burning Rock Biotech (NASDAQ: BNR) and Dizal have jointly announced the approval of the first co-developed NGS-based companion diagnostic (CDx) for lung cancer by China's National Medical Products Administration (NMPA). This CDx is designed for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, marking a significant milestone in precision...
what a stock, no volume but circuit breaker multiple times
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
Burning Rock Biotech (NASDAQ: BNR) has announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) in China. This partnership aims to enhance diagnostic methods and enable better treatment choices for cancer patients. The collaboration will focus on developing CDx products for Bayer's precision cancer therapies...
No comment yet